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Abstract
The effects of Castanea sativa Mill. have been studied in high fat diet (HFD) overweight
rats. Natural Extract of Chestnut bark (Castanea sativa Mill.) (ENC®), rich in ellagitannins,
has been studied in 120 male Sprague-Dawley rats, divided in four groups. Two groups
were controls: regular (RD) and HDF diet. Two groups received ENC® (20 mg/kg/day): RD +
ENC® and HFD + ENC®. At baseline and at 7, 14 and 21 days, weight gain, serum lipids,
plasma cytokines, liver histology, microsomial enzymes and oxidation, intestinal oxidative
stress and contractility were studied. HFD increased body weight, increased pro-inflamma-
tory cytokines, induced hepatocytes microvescicular steatosis, altered microsomial,
increased liver and intestinal oxidative stress, deranged intestinal contractility. In HFD-fed
rats, ENC® exerted antiadipose and antioxidative activities and normalized intestinal con-
tractility, suggesting a potential approach to overweight management associated diseases.
Introduction
Unhealthy sedentary lifestyle and excessive eating have influenced the increase of closely
related disturbances, such as obesity, insulin resistance, hypertension, and dyslipidemia, and
the outstanding example of metabolic syndrome [1]. Metabolic syndrome is characterized by
chronic dysregulation of metabolic and immune processes [2], low-grade inflammation [3],
antioxidant impairment [4], xenobiotic metabolism homeostasis disruption [5], vascular
smooth muscle contractility alterations [6]. Increased oxidative stress (OS) in obese patients
[7] appears to be involved in the onset and progression of the pathological alterations of differ-
ent organs [8–12]. Obesity-induced inflammatory dysfunctions may be, at least in part,
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reversible by “Comprehensive lifestyle interventions” [13]. Nutraceuticals use in the preclinical
phase is a “proactive reverse approach” tool to health conditions in prevention time [14] and
studies are being conducted to understand the mechanisms of action of bioactive nutraceutical
compounds.
Traditionally, Castanea sativa Mill. leaves or bark has been widely used against various dis-
eases, for its high antioxidant [15], cardioprotective activity [16], antihelmintic, antibacterial
and antiviral effects [17], neuroprotective activity [18, 19], antispasmodic action on gallbladder
[20] and intestine [15, 21].
High levels of tannins and their antioxidant activity have suggested that Castanea sativa
Mill. bark extract associated to diet as a supplement, can help to prevent and treat the patho-
logical processes underlying obesity.
In this study, we show the protective effect of Natural Extract of Chestnut [ENC1 (Casta-
nea sativa Mill. bark extract)] on body weight gain, liver inflammation and function, liver and
intestinal oxidative state, gastric and intestinal contractility in high-fat diet rats in order to pro-
pose its use in the prevention and possibly co-management of obesity.
Materials and methods
Plants materials and chemicals
Bark extract of a Castanea sativa Mill. (ENC1), (supplied by SilvaTeam S.p.a., San Michele
Mondovı`, Italy) was obtained with a process previously described [21]. The powder (92–95%
dry matter) is made by 77% tannins and its chemical composition has been previously charac-
terized by HPLC-DAD-MS analysis. [16]. It is rich in phenolic compounds such as: castalin,
vescalin, castalgin, vescalgin, ellagic acid and gallic acid. The amount of ellagic acid and of gal-
lic acid found in ENC1 were 10.69 ± 0.28% and 24.01 ± 0.57% respectively. The extract used
in the study has been obtained as previously described and the percentage composition of the
phenolic compounds has been obtained. Further information about ENC1 is available at SIL-
VATEAM website (http://it.silvateam.com/). Detailed information about chemicals are listed
in S1 File.
Animals and experimental design
120 male Sprague-Dawley rats were purchased from Envigo RMS S.R.L. San Pietro al Natisone
(Udine, Italy) at 9 weeks of age weighing 270–300 g. They were housed over 7 days adaptation
under 12h-light/12h-dark cycle, 22˚C, 60% humidity, with water and food ad libitum. The rats
were split randomly into two groups and fed specific diets as follows: regular diet (RD, n = 60:
18.7% crude protein, 5.6% crude fat, 4.5% crude fibre by Mucedola s.r.l.); high fat diet (HFD,
n = 60: 23% crude protein, 34% crude fat, 5% crude fibre, by Mucedola s.r.l.). HFD has been
reported in S2 File. Animals maintained the dietary regimens described for 10 weeks, then
each group was assigned to the treatment as follows: RD animals with vehicle (tap water)
(n = 30), RD animals with ENC1 20 mg/kg administered by gavage (n = 30), HDF group with
vehicle (tap water) (n = 30), HFD diet with ENC1 20 mg/kg administered by gavage (n = 30).
(Fig 1). The dose of ENC1 to be administered to rats was extrapolated by using the transla-
tional dose calculation [22], which express the human equivalent dose (HED, mg/kg) as:
HED ¼ Animal dose
Animal Km
Human Km
where Km was 6 and 37 for rat and human, respectively. As Abidov used 300 mg/day in man, a
value in agreement with the human dose of 225 mg/day [23], the resulting final dose for rat
was thus calculated to be 20 mg/kg. Furthermore, 21 days of treatment was chosen as it is the
Castanea sativa Mill. bark extract in high-fat diet rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0201540 August 6, 2018 2 / 19
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have read the
journal’s policy and have the following conflicts: AC
is affiliated with GVM Care & Research but did not
receive a salary. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing
data and materials.
most common duration period to highlight metabolic changes and possible toxic effects and to
better evaluate the time-course of the observed changes. At every end point (7, 14, 21 days) the
animals were sacrificed by decapitation (n = 10/ end point) and the parameters reported.
Ethical statements
The work was conducted according to the guidelines set forth to EU Directive 2010/63/EU
and to ARRIVE guidelines [24]. The protocol was approved by the Institutional Ethics Com-
mittee of the University of Bologna (Protocol 21/79/14) and transmitted to the Ministry of
Health. Details of Humane end points.docx are in S3 File.
Body-weight gain and food intake
Body weight and food consumption measurements started the first day of the study and con-
tinued for the entire experiment (3 weeks).
Determination of lipids, transaminases and inflammation
Serum lipids and transaminases. Triglyceride, HDL-cholesterol, LDL-cholesterol, total
cholesterol and transaminases (ALT and AST) concentrations were measured by using com-
mercially available kits (see S4 File).
Plasma inflammatory response. Biomarkers of inflammation have been quantitatively
evaluated in RD- and HFD- rats, in basal conditions and after ENC1 addition: IL-1α, IL-1β,
IL-2, IL-5, IL-6, IL-7, IL-12p70, IL-17A, IL-18, and TNF-α (pro-inflammatory) and IL-4, IL-
Fig 1. Overview of the experimental design. After one-week housing period, animals were randomly assigned to RD or HFD groups (10-weeks
fattening period). HFD and control rats were further split into 4 groups as depicted. Animals were treated for 7, 14 or 21 days during which they
received ENC1 (20 mg/kg/day) or vehicle (tap water).
https://doi.org/10.1371/journal.pone.0201540.g001
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10, IL-13 (anti-inflammatory), by the Luminex MAGPIX1 system (Millipore Corp., Billerica,
MA, USA). For details, see S4 File).
Histology
Liver necro-inflammatory score and architectural changes, fibrosis and cirrhosis were assessed
after haematoxylin and eosin tissue staining (See S4 File).
Hepatic Phase I, Phase II and antioxidant enzyme activities
Tissue collection and preparation of hepatic subcellular fractions, Phase I and II, antioxidant
enzymes and their activities, listed below, were assessed as reported in S4 File).
Phase I. NADPH-(CYP)-c-reductase (CYP-red), Aminopyrine N-demethylase (APND)-
CYP3A1/2, p-Nitrophenol hydroxylase (p-NFH)-CYP2E1, Pentoxyresorufin O-dealkylase
(PROD)-CYP2B1/2, Ethoxyresorufin O-deethylase, (EROD)-CYP1A1, Methoxyresorufin O-
demethylase (MROD)-CYP1A2, Ethoxycoumarin O-deethylase (ECOD)-CYP1A1/2.
Phase II. Glutathione S-transferase (GST) activity, UDP-glucuronosyl transferase
(UDPGT).
Antioxidant enzymes. Catalase (CAT) activity, NAD(P)H:quinone reductase (NQO1),
Oxidised glutathione reductase activity (GSSG-red), Superoxide dismutase activity (SOD).
Oxidative stress evaluation in ileal and colonic tissues
OS biomarkers were evaluated in colon and ileum by assay: Details are reported in S4 File).
Spontaneous and induced contractility studies
Gastric fundus basal contractility was investigated. Ileum and proximal colon induced contrac-
tility were studied against cholinergic receptors and calcium channels (S4 File).
Data presentation and statistical analysis
Results are presented as mean ± standard deviation (S.D.) or error standard (S.E.M.) from n
rats. The experimental design was subjected to ‘a priori power analysis’ to ensure that the size
of treated- and control- groups was adequate (GPower v. 3.1.9.2). To improve clarity, since
the content of serum lipids and transaminase, plasma pro- anti-inflammatory cytokines, MDA
in ileum and colon as well as hepatic Phase I, II and antioxidant enzyme activities did not
change significantly between day 0 and day 21 in both RD- and HFD-rats, these have been
pooled and reported as RD 0–21 or HFD 0–21. Plasma cytokine content was reported as per-
cent changes of the baseline value [100 (%)] of RD-rats. Data were compared by ANOVA fol-
lowed by Bonferroni’s post hoc tests and in all comparisons, P value less than 0.05 was
considered significant. Before performing the analysis, ANOVA assumption were always
tested using the method of Bartlett (data sampled from populations with identical SDs) and
Kolmogorov and Smirnov (data sampled from populations that follow Gaussian
distributions).
Changes in spontaneous contractions of gastric fundus were considered significant when
they were higher than 10% variations in each range [25].
Functional induced contractility of agonist Carbacol (CCh) was expressed as pEC50 values.
The antagonism activity of atropine against CCh was expressed as pA2 values determined from
Schild plots [26] constrained to slope –1.0, as required by theory [27]. Differences between
mean values were performed by using a two-tailed unpaired Student’s t-test for continuous
data. In all comparisons, P value less than 0.05 was considered significant.
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Results
Body weight gain and food intake
Three weeks of HFD increased significantly rat body weight, with respect to RD (598.1 ± 41.4
g vs 455.8 ± 20.0 g, P< 0.01), despite a general lower food intake of the former group (Fig 2).
In RD-rats, weight, weight gain and food intake did not show significant differences with
ENC1, while in HFD-rats ENC1 caused a significant decrease in food intake and weight gain
with respect to HFD-rats (Fig 2).
It is worth outlining that 21 days of ENC1 treatment did not cause any death in either RD-
or HFD-rats. Moreover, physical observations of treated animals showed no signs of changes
in the skin, fur, eyes mucous membrane, behavior patterns, tremors, salivation, suggesting an
apparent safe profile of ENC1 treatment.
Liver gross appearance and histology
RD-rats presented normal liver histology, while HFD induced a moderate hepatocytes micro-
vesicular steatosis; after ENC1 microvesicular steatosis was only in scattered hepatocytes (Fig
3), with a regression of liver steatosis. The livers did not present any sign of necroinflammatory
score (arbitrary score of 0 on a scale range from 0 to 18). Similarly, the gross appearance of the
liver showed an enlargement and lightening in color that decreased after ENC1 assumption.
Histological parameters are detailed in S1 Table.
Lipids, transaminases and inflammation
Serum lipids and transaminases. As reported in Table 1, HFD-rats serum cholesterol lev-
els were higher than those of RD-rats (P< 0.01 vs RD 0–21). Cholesterol was significantly low-
ered by ENC1 administration in HFD-rats (-10%, P< 0.05). LDL Cholesterol was higher in
HFD rats than in controls (P< 0.05 vs RD 0–21); ENC1 decreased LDL levels in HFD-rats
(P< 0.05 vs HFD 0–21), while it left them unchanged in RD-rats. At the beginning of the study,
HDL Cholesterol was lower in HFD- than in RD-rats (P< 0.05 vs RD 0–21). ENC1 increased
HDL in the HFD group (P< 0.05 vs HFD0-21), whereas it did not affect that of RD-rats. Tri-
glycerides were increased by about 63% in HFD with respect to RD- rats (P< 0.01 vs RD 0–21);
interestingly, in the former group ENC1 decreased triglycerides levels (P< 0.01 vs HFD 0–21).
Fig 2. Body weight, food intake and weight gain of RD-rats, HFD-rats with or without ENC1 (20 mg/kg/day) for 21 days. RD 0 or HFD 0: data measured at day 0;
RD 21 or HFD 21: data measured at day 21. Results are reported as mean ± S.D. (n = 10/group) and analyzed by using ANOVA followed by Bonferroni post test.
P< 0.01 vs RD-fed group, same time. ˚P< 0.05 vs HFD21.
https://doi.org/10.1371/journal.pone.0201540.g002
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Finally, aspartate transaminases and alanine transaminases were not affected by the treatment
in both RD- and HFD-rats. RD-rats and HFD-rats with or without ENC1 (21 days).
Inflammatory response. HFD-rats had higher pro-inflammatory cytokines plasma levels
than RD-rats (Fig 4), changing from + ~ 30% (IL-1ß) to +~ 600% (IL-6). In the former group,
however, 21 days ENC1 decreased significantly IL1α, IL-2, IL-6, IL-12p70, IL17A and TNF-α
plasma levels, while it left unchanged those of IL-1ß, IL-5 and IL-18. Interestingly, the anti-
inflammatory cytokines IL-4, IL-10 and IL-13 were significantly lower in overweight animals
Fig 3. Histology of liver tissues (upper panels) and gross appearance of the liver (lower panels) of RD-rats, HFD-rats with or without ENC1 (20 mg/kg/day) for
three weeks. A: RD control rat: normal rat liver showing central vein and a regular parenchyma. B: RD rat after ENC1: the liver shows a normal portal tract and mild
hepatocyte pleomorphism. C: HFD rat: the hepatocytes show a moderate microvescicular steatosis. D: HFD rat after ENC1: microvescicular steatosis is evident only in
scattered hepatocytes. (H&E) 10x.
https://doi.org/10.1371/journal.pone.0201540.g003
Table 1. Serum parameters of RD-rats and HFD-rats supplemented with or without ENC1 for 21 days.
RD RD+ ENC1a HFD HFD+ ENC1a
Day 0–21 21 0–21 21
ASTb 242 ± 60 236 ± 70 237 ± 60 238 ± 60
ALTc 67 ± 23 64 ± 25 60 ± 23 60 ± 21
Cholesterold 3.16 ± 0.23 3.10 ± 0.19 3.68 ± 0.17 3.28 ± 0.16˚
LDL Cholesterold 0.90 ± 0.03 0.88 ± 0.09 1.02 ± 0.02 0.92 ± 0.07˚
HDL Cholesterold 2.34 ± 0.08 2.36 ± 0.03 2.18 ± 0.04 2.26 ± 0.03˚
Triglycerided 1.24 ± 0.14 1.22 ± 0.16 2.03 ± 0.10 1.46 ± 0.07˚˚
a) ENC1 20 mg/kg/day.
b) AST, Aspartate transaminases (Units/ml).
c) ALT, Alanine transaminases (Units/ml).
d) Expressed as mmol/l.
To improve clarity, since values between RD 0 day and RD 21 days did not change significantly, they have been pooled; the same was for HFD 0 day and HFD 21 days.
Results are reported as mean ± S.D. (n = 10/group) and analyzed by using ANOVA followed by Bonferroni post test.
P< 0.05
P< 0.01, vs RD-rats, same time.
˚P< 0.05
˚˚P< 0.01 vs HFD 0–21.
https://doi.org/10.1371/journal.pone.0201540.t001
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(- 50–60%, P<0.05 or 0.01 vs RD 0–21) (Fig 5). ENC1 reverted this effect, restoring anti-
inflammatory cytokines plasma content to values very close to RD-rats. Finally, ENC1 did not
affect cytokines plasma contents in RD-rats.
Hepatic Phase I, Phase II and antioxidant enzyme activities
Hepatic Phase-I enzymes. In RD-rats, ENC increased the activity NADPH cyp red, APD
and PROD, leaving unaffected that of pNPH, ECOD, EROD and MROD (Fig 6). Also HFD-
rats reported a widespread increment of microsomal hepatic mono-oxygenases respect to RD-
Fig 4. Plasma pro-inflammatory cytokines in RD-rats, and HFD-rats with or without ENC1 (20 mg/kg/day) for 21 days. RD0-21 or HFD0-21: pooled data between
days 0–21. Data are reported as mean ± S. D. and expressed as a percent changes of the baseline value [100 (%)] of RD-fed rats. P< 0.05, P< 0.01, P< 0.001 vs
RD same time. ˚P< 0.05, ˚˚P< 0.01 vs HFD 0–21 (ANOVA followed by Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.g004
Fig 5. Plasma anti-inflammatory cytokines in RD-rats, and HFD-rats with or without ENC1 (20 mg/kg/day) for 21 days. RD0-21 or HFD0-21: pooled data
between days 0–21. Data are reported as mean ± S.D. and expressed as percent changes of the baseline value [100 (%)] of RD-rats. P< 0.05, P< 0.01, P< 0.01 vs
RD same time. ˚P< 0.05, ˚˚P< 0.01 vs HFD 0–21 (ANOVA followed by Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.g005
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rats. In particular, CYP3A1/2, CYP2E1 and CYP1A2 isoform-linked activities, here measured
as APD, p-NPH and MROD, respectively as well as NADPH cyp-red were significantly raised
(P< 0.01 vs RD0-21) (Fig 6), while ECOD and EROS were not changed. ENC1 was effective
in counteracting the changes caused by HFD, reducing almost all enzymes increased activities
(P< 0.01 vs HFD 0–21). Hepatic phase-I enzymes full changes are detailed in S2 Table.
Hepatic phase-II enzymes. ENC1 supplementation induced a significant up-regulation
of GST activity in both RD- ( 78%, P< 0.01) and HFD-rats (66%, P< 0.01) (Fig 7). In
HFD-rats, UDPGT was decreased with respect to RD-rats and ENC1 restored the values
toward those observed in RD-rats. Detailed information is in S2 Table.
Hepatic antioxidant enzymes. Hepatic antioxidant enzymes CAT and NQ01 were similar
in RD and HFD rats. On the contrary, as shown in Fig 8, HFD decreased SOD and GSSG-red
with respect to RD. In RD feed rats, the treatment with ENC1 increased CAT and SOD and
decreased NQ01 activities, while in HFD animals, it caused an increment of CAT, SOD and
GSSG-red, completely restoring these enzyme antioxidant potential which exceeded the values
recorded in RD group (Fig 8). For detailed information about the changes in the time course
of antioxidant enzymes activities, see S2 Table.
Oxidative stress in ileal and colonic tissues
Malondialdehyde (MDA) assay, a product generated from lipid oxidation, was used to mea-
sure the level of OS in the different tissues. HFD-rats showed a significant increase in the
Fig 6. Changes in liver phase-I enzymes in RD-rats, and HFD-rats with or without ENC1 (20 mg/kg/day) for 21 days. RD0-21 or HFD0-21: pooled data between
days 0–21. Bars represent the means ± S.D. P< 0.05, P< 0.01, vs RD same time; ˚P< 0.05, ˚˚P< 0.01, ˚˚˚P< 0.001 vs HFD0-21; ## P<001 vs RD0-21.
https://doi.org/10.1371/journal.pone.0201540.g006
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MDA values respect to RD-rats (P< 0.01 in the ileum and P<0.001 in the colon) confirming
that a HFD induces OS (Fig 9). Interestingly, the RD-rats, treated with ENC1 for 21 days had
a high MDA value in the ileum suggesting that the phenolic compounds present in the ENC1
may have a pro-oxidant effect on this tissue at the dose of extract used. Nevertheless, 21 days of
ENC1 administration was able to counteract HFD-induced OS in the ileum (Fig 9). The pro-
oxidant effect of ENC1 in RD-rats was not evident in colon tissue. On the other hand, OS
induced by the HFD on this tissue was 2.5 times higher than that of the RD-rats (P< 0.001);
after 21 days ENC1treatment MDA was significantly reduced (P< 0.01 vs HFD 0–21) con-
firming the antioxidant properties of ENC1 (Fig 9).
Spontaneous and induced contractility studies
Spontaneous contractility. The gastric spontaneous contractility in HFD-rats was charac-
terized by a higher basal tone than in RD-rats (P< 0.01). After ENC1 the basal tone was
unchanged in RD-rats while in HFD-rats the contraction force was reduced to values within
the range of RD-rats, suggesting that 21 days ENC1 treatment restored the gastric tonic state
to values within the normal range (Fig 10).
Induced contractility. Ileum- and distal colon-induced contractility by Carbachol (CCh)
and KCl (80 mM) was studied. In RD-fed rats, CCh caused a rapid phasic response, while KCl
induced a tonic contraction of rat ileum and proximal colon, as previously reported [25].
Fig 7. Changes in liver phase-II enzymes in RD-rats, and HFD-rats with or without ENC1 (20 mg/kg/day) for 21 days. RD0-21 or HFD0-21: pooled data between
days 0–21. Bars represent the means ± S.D. ##P< 0.01 vs RD0-21; P< 0.01 vs RD same time; ˚˚P< 0.01 vs HFD0-21.
https://doi.org/10.1371/journal.pone.0201540.g007
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Atropine antagonized in concentration dependent manner the response to CCh both in ileum
and colon (Table 2 and S3 Table).
In ileum, HFD significantly reduced CCh and atropine pA2 (P< 0.01) with respect to RD-
rats; ENC1 decreased CCh pD2 difference (P<0.05). In ileum ENC1 did not change CCh pD2
after days 21 treatment in HFD-rats, while atropine pA2 values were not different from RD-
rats. In RD-rats proximal colon, ENC1 slightly reduced CCh potency, less than in the ileum,
and Atropine potency. In HFD-rats colon, both CCh and Atropine were less potent than in
Fig 8. Changes in hepatic antioxidant enzymes after 21 days ENC1 supplementation (20 mg/kg/day) in RD-fed and HFD-fed
rats. RD0-21 or HFD0-21: pooled data between days 0–21. Bars represent the means ± S.D. of ten measurements performed on ten
rats.  P< 0.01 vs RD-fed group, same time. ˚˚P< 0.01, ˚˚˚ P<0.001 vs HFD0-21, ##P< 0.01 vs RD0-21.
https://doi.org/10.1371/journal.pone.0201540.g008
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Fig 9. MDA equivalents in ileum and colon homogenates in RD-rats and HFD-rats supplemented with or without ENC1 (20 mg/kg/day) for 21 days. Data are
expressed as mean ± SD. P< 0.01, P< .001 vs RD same time. ˚P< 0.05, ˚˚P< 0.01 vs HFD0-21 (ANOVA followed by Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.g009
Fig 10. Basal gastric spontaneous contractility in RD- (panel A) and HFD-rats (panel B) before and after 21 days supplementation with ENC1 (20 mg/kg/day).
Panel C: columns comparing the specific values for RD- and HFD-rats. Data are expressed as mean ± SD. P< 0.01, vs RD same time; ˚˚P< 0.01 vs HFD0-21
(ANOVA followed by Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.g010
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the same organs of RD-rats. In RD-rat ileum and proximal colon, Nifedipine inhibited tonic
contraction induced by 80 mM KCl (Fig 11) (for detailed data, see S3 Table).
After ENC1 administration, no significant changes in Nifedipine intrinsic activity and
potency were observed in RD-fed rats ileum. In HFD-fed rats ileum, Nifedipine showed the
same intrinsic activity, but at concentrations which differ by one order of magnitude (Fig 11)
(For detailed data, see S3 Table). Potency on the HFD-fed rats ileum was about 16.39 times
lower than on RD-fed rats. After 21 days ENC1 treatment, Nifedipine potency was not quite
different from that observed in RD-fed rats ileum. In RD-fed rats colon, Nifedipine potency
decrease was related to the days of treatment and became lower by 4.04 at the end of the exper-
iment (21 days of treatment). In HFD-fed rats colon, Nifedipine presented intrinsic activity
and potency significantly different from RD-fed rats colon. Potency was reduced by 37.72
times. 21 days ENC1 treatment of HFD-fed rats increased Nifedipine potency on the colon,
which attained values very close to those observed in RD-fed rats colon (Fig 11) (for detailed
data, see S3 Table).
Discussion
Polyphenols have been shown to exert several beneficial effects in different obesity experimen-
tal models [16, 20, 29–31], by scavenging reactive oxygen and nitrogen species and modulating
genes associated with metabolism, drug metabolizing enzymes, detoxification proteins, pro-
tecting from chronic diseases [32].
A down-regulation of liver oxidative defenses has been reported in obesity experimental
models [33]. Consistently, in the present work, ENC1 restored the antioxidant enzymatic abil-
ity in HFD-rats and suppressed pro-inflammatory / anti-inflammatory cytokines imbalance in
HFD rat liver. A crucial point is the decrease of TNF-α, a key factor in the development of
Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
[34], of IL-6, hepatoprotector in liver steatosis by reducing oxidative stress [35], of IL-10 [36]
and of IL-17A, implicated in both regulation of obesity and NAFLD [37].
Table 2. Agonist [carbachol (CCh)] and antagonist (atropine) activities expressed as pEC50 or pA2, respectively, in ileum and proximal colon of RD- and HFD-rats
supplemented with or without ENC1 for 21 days.
RD RD + ENC1a HFD HFD+ ENC1a
Day 0–21 21 0–21 21
Ileum CCh b 6.27 ± 0.03 6.34 ± 0.05 5.89 ± 0.02 5.90 ± 0.04
Atropine c 8.95 ± 0.03 8.90 ± 0.05 8.68 ± 0.04 8.91 ± 0.02
Proximal Colon CCh b 5.92 ± 0.02 5.80 ± 0.02## 5.83 ± 0.03 5.43 ± 0.02˚˚
Atropinec 8.77 ± 0.03 8.57 ± 0.04## 7.73 ± 0.07 8.73 ± 0.02˚˚
a) RD-and HFD-rats have been given 21 days ENC1 (20 mg/kg/day b.w).
b) Data are expressed as pEC50. pEC50 = –log EC50. EC50 values are the means ± S.E.M. of at least four independent experiments and were calculated by a non-linear
regression curve-fitting computer program [28] [50]
c) Data are expressed as pA2. pA2 values ± S.E.M. were calculated from Schild plots [26], constrained to slope –1.0 [27] (pA2 is the positive value of the intercept of the
line derived by plotting log (DR– 1) vs log [antagonist]. The log (DR– 1) was calculated from three different antagonist concentrations, and each concentration was
tested from four to six times. Dose-ratio (DR) values represent the ratio of the potency of the agonist carbachol (EC50) in the presence of the antagonist and in its
absence. Parallelism of concentration–response curves was checked by linear regression, and slopes were tested for significance (P< 0.05).
P<0.05
P< 0.01
P<0.001 vs RD, same time.
˚˚P< 0.01, vs HFD0-21.
## P< 0.01 vs RD0-21 (ANOVA followed by Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.t002
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NAFLD is characterized by a general dysregulation of drug metabolism enzymes. Several
studies reported that GSTM1, GSTM2, GSTM4 and GSTM5 mRNA levels are suppressed in
patients with steatosis and NASH [38]. Moreover, GST activity decreases with disease progres-
sion with a reduced pool of glutathione, highlighting the reduced ability to counteract OS in
these patients [39].
Finally, GSTM1-null genotype has been associated to NAFLD [40] and UDPGT levels were
decreased in HFD-fed rats [41]. In HFD-rats ENC1 increased enzymatic activity of GST and
UDPGT and it can reduce the dysregulation of drug metabolism enzymes. Moreover, these
finding could be clinically relevant for obese patients who have additional comorbidities and
are receiving multiple medications.
These outcomes are extremely important in a therapeutic schedule of obese patients at pos-
sible risk of NAFLD and NASH. ENC1 slightly reduced liver steatosis induced by HFD. Since
flavonoids induce a cytoprotective effect through Nrf2-dependent gene expression [42] we
think that up-regulation of antioxidant and detoxifying enzymes is obtained of Nrf2-ARE sig-
nalling pathway. Intracellular accumulation of xeno- and endobiotics is regulated at several
levels by drug metabolizing enzymes.
Many tannins possess anti-obesity properties [43]. Pomegranate leaf extract containing
abundant tannins, for example, can hamper the development of obesity and hyperlipidemia in
Fig 11. Potency of Nifedipine (pEC50) on ileum and distal colon in RD-and HFD-rats with or without ENC
1 (20 mg/kg/day) for 21 days. The spasmolytic effect
induced by Nifedipine was used as reference. Data are expressed as mean ± S.E.M.. P<0.05, P<0.01 vs RD0-21; ˚P<0.05, ˚˚P<0.01 vs HFD 0–21 (ANOVA followed by
Bonferroni post test).
https://doi.org/10.1371/journal.pone.0201540.g011
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high-fat diet induced obese mice by inhibiting the pancreatic lipase activity and suppressing
energy intake [44]. This effect was much less evident when the animals were treated with its
main isolated compounds (ellagic acid and tannic acid), suggesting a possible synergic effects
among the component of the extract. Furthermore, growing number of studies demonstrate
the potential role of ellagic acid in the regulation of lipid metabolism and in attenuating obesity
and metabolic syndrome in rodents, mainly because of its antioxidant and anti-inflammatory
properties (for a review see [45]). Thus it is possible that all the properties reported for ellagic
acid are shared also by ENC1 or its gut metabolites. Is is important to outline, however, that
the amount of ellagic- and gallic-acid contained in ENC1 is ~ 1–2% of the injected dose, sug-
gesting that other components may contribute to the observed effects. It is possible that other
polyphenols found in ENC1 might act synergistically by increasing, for example, the potency
of ellagic and gallic acids at its specific molecular target(s) or by increasing the bioavailability
of the main active components. In this sense, the literature already reports the existence of syn-
ergistic effects among several phytochemicals [46].
Obesity has been correlated with an induction of some cytochrome P450 isoforms (CYPs)
[5, 47, 48]. The NADPH-dependent overproduction of reactive oxygen species (ROS) is linked
to CYP induction [49].
In HFD-rats an up-regulation of mainly CYP2E1, CYP3A1 and CYP2B1/2 CYPs has
been found. CYP2E1 values were reduced by four times by ENC1. CYP2E1 up-regulation has
been associated to obesity, fatty liver, and NASH in both humans and rodents and correlates
with NAFLD severity [50] and progression of liver steatosis to NASH: CYP2E1 up-regulation
leads to enhanced ROS production, with an increase of lipid peroxidation and inflammation
[51].
HFD led to a general impairment of cellular redox homeostasis responsible for the observed
alterations of phase I and II antioxidant enzymes. We focused on the peroxidation products in
intestinal tissues from all experimental groups. In RD-rats ileum, ENC1 increased MDA lev-
els, likely due to the high amount of ellagitannins, that are slowly hydrolysed in the digestive
tract, to release ellagic acid. In the colon OS was increased, as observed in the mouse distal
colon of HFD mice [52].
The compound inhibited HFD-induced oxidative stress increase, in agreement with pub-
lished data showing that polyphenols rich extracts provide benefits in gut inflammation, for
their antioxidant activity, due to a prebiotic [53] action that may help reduce OS in obese
patients.
Since obesity seems associated to increased gastric emptying, we evaluated the basal gastric
tone of HFD- and RD-rats. ENC1 restored the gastric tone in HFD-fed rats. HFD alters the
composition of cells membranes, resulting in an impaired response to endogenous agonists
such as Ach and histamine; also intracellular calcium release may be disturbed. In a previous
work, we demonstrated that ENC1 exerts a non-competitive and concentration-dependent
antagonist effect towards muscarinic and histaminergic receptors and inhibits BaCl2-induced
contractions: these effects may be, at least in part, responsible for ENC1 beneficial effects
towards gastric smooth muscle contractility alterations related to obesity [21]. To evaluate the
intestinal cell membrane functionality, we used CCh and atropine as a muscarinic receptor
agonist and antagonist respectively, and nifedipine as calcium channel blocker. ENC1 spas-
molytic effect depends on a combination of effects towards different receptors and channels.
KCl induced tonic contraction on rat ileum and colon while CCh caused a rapid phasic con-
traction. Nifedipine completely inhibited K+ induced contraction. In RD-rats, ENC1 (21
days) reduced nifedipine potency by 4.04 times in the colon, with a minimal decrease in
the ileum (by 1.69 times). Hypercholesterolemic diet has been reported to decrease calcium
channel pump activity in pigs coronary macrocirculation [54] and cholesterol enriched
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cyclodextrin inhibited calcium currents in guinea pig gallbladder smooth muscle [55]. In
HFD-rats, nifedipine potency was 16.39 and 37.72 times less potent than in RD-rats ileum and
colon, respectively. Importantly, ENC1 decreased the activity of L-type calcium channels in
RD-rats mainly in colon, but increased their function mostly in the HFD-rats colon. ENC1
decreases nifedipine potency in ileum and more strongly in colon. Therefore, in HFD-rats cal-
cium channels function progressively recovers after ENC1 administration.
The activity and responsiveness of calcium channels in HFD-fed rats may be worthwhile
considering. The induced increase in calcium channels activity may influence the basal tone,
affect contractility and alter the response to receptor agonists and antagonists. ENC1 showed
a not competitive and reversible muscarinic effect on isolated ileal and colonic muscular strips
and ENC1 restored receptors function in HFD-rats. Also in the case of membrane coupled
receptors, the observed increase of the activity showed the restoration of membrane function,
that supported the ENC1 effects on basal gastric contractility.
Conclusions
In conclusion, our study shows that ENC1 may be a promising nutraceutical tool, decreasing
spontaneous food assumption, up-regulating hepatic antioxidant enzymes causing the
impairment in liver oxidative defenses, restoring liver phase I and II enzymes activity, reducing
intestinal oxidative stress, and restoring the intestinal motor function. These ameliorative
effects on metabolic situation in obesity might be related to the presence of ellagic and gallic
acid. As recently reported on hypertriglyceridemia induced by High-Fructose Diet in rats,
ENC1 contains such gallic acid equivalents as to decrease hypercholesterolemia induced by
HFD [56]. All together these results show that ENC1 has the potential to be used in clinical
medicine as a dietary supplement in the treatment of obesity complications.
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